<code id='087DCC256A'></code><style id='087DCC256A'></style>
    • <acronym id='087DCC256A'></acronym>
      <center id='087DCC256A'><center id='087DCC256A'><tfoot id='087DCC256A'></tfoot></center><abbr id='087DCC256A'><dir id='087DCC256A'><tfoot id='087DCC256A'></tfoot><noframes id='087DCC256A'>

    • <optgroup id='087DCC256A'><strike id='087DCC256A'><sup id='087DCC256A'></sup></strike><code id='087DCC256A'></code></optgroup>
        1. <b id='087DCC256A'><label id='087DCC256A'><select id='087DCC256A'><dt id='087DCC256A'><span id='087DCC256A'></span></dt></select></label></b><u id='087DCC256A'></u>
          <i id='087DCC256A'><strike id='087DCC256A'><tt id='087DCC256A'><pre id='087DCC256A'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:812
          Ron Wyden (left), Mike Crapo (right) -- health policy coverage from STAT
          Draft legislation authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho) includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers. Pete Marovich-Pool/Getty Images

          WASHINGTON — A key Senate health care panel has developed a plan to tackle reforms to middlemen in the pharmacy drug payment system, according to bill text obtained by STAT.

          The draft legislation, authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho), includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers.

          advertisement

          The most significant measure is a bill from Sens. Bob Menendez (D-N.J.) and Marsha Blackburn (R-Tenn.) that would prohibit PBMs from getting any income outside of service fees, and prohibits those service fees from being related to drugs’ list prices.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Digital health: a case of mistaken identity
          Digital health: a case of mistaken identity

          AdobeHistoryandliteraturearerepletewithcautionarytalesonthedangersofpretendingtobesomeone—orsomethin

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Paxlovid rebound happens. Why and to whom are still a mystery

          TheCovidantiviraldrugPaxlovidisdisplayedinNewYork.StephanieNano/APAsanemergencydepartmentphysicianin